The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives
Abstract
beta-Amyloid precursor protein (beta-APP), the source of the fibrillogenic amyloid beta-peptide (A beta) that accumulates in the brain of victims of Alzheimer's disease, is a multifunctional protein that is widely expressed in the nervous system. beta-Amyloid precursor protein is axonally transported and accumulates in presynaptic terminals and growth cones. A secreted form of beta-APP (sAPP alpha) is released from neurons in response to electrical activity and may function in modulation of neuronal excitability, synaptic plasticity, neurite outgrowth, synaptogenesis, and cell survival. A signaling pathway involving guanosine 3',5'-cyclic monophosphate is activated by sAPP alpha and modulates the activities of potassium channels, N-methyl-D-aspartate receptors, and the transcription factor NF kappa B. Additional functions of beta-APP may include modulation of cell adhesion and regulation of proliferation of nonneuronal cells. Alternative enzymatic processing of beta-APP liberates A beta, which has a propensity to form amyloid fibrils; A beta can damage and kill neurons and increase their vulnerability to excitotoxicity. The mechanism involves generation of oxyradicals and impairment of membrane transport systems (e.g., ion-motive ATPases and glutamate and glucose transporters). Genetic mutations or age-related metabolic changes may promote neuronal degeneration in Alzheimer's disease by increasing production of A beta and/or decreasing levels of neuroprotective sAPP alpha.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Altering levels of APP and of sAPPα, a growth factor [262], may impact AD more than altering Aβ levels.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [262]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Sorted by citations
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Self-citationNeurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Impact of intermittent fasting on health and disease processes
Mattson, M. P., Longo, V. D., & Harvie, M. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.005 · Cited by 1,187
“A is generated from APP by sequential enzymatic cleavages by - and -secretases, and presenilin 1 is the enzymatic subunit of the -secretase enzyme complex (Mattson, 1997).”
Self-citationAmyloid Precursor Protein Trafficking, Processing, and Function
Thinakaran, G., & Koo, E. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800019200 · Cited by 1,141
Metadata
- Authors
- Mattson, M. P.
- Affiliations
- University of Kentucky (US)
- Corresponding author
- Mattson, M. P.
- ORCID
- Mattson, M. P.
- Venue
- Physiological Reviews
- Publisher
- American Physiological Society
- Published
- 1997-10-01
- Volume
- 77
- Issue
- 4
- Pages
- 1081-1132
- ISSN
- 0031-9333 (ISSN-L)
- 1522-1210
- OpenAlex
- W1762207349
- Cited by
- 1,006
- References
- 0
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 13 · 2023: 22 · 2022: 12 · 2021: 17 · 2020: 20 · 2019: 14 · 2018: 26 · 2017: 23 · 2016: 27 · 2015: 30 · 2014: 38 · 2013: 31 · 2012: 43
- FWCI
- 29.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Physiological Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns029001-07, 5r01ns030583-04)
- National Institute of Neurological Disorders and Stroke (NS29001, NS30583)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid precursor protein, soluble APP alpha, amyloid-beta, Alzheimer's disease, axonal transport, presynaptic terminals, neuronal excitability, synaptic plasticity, neurite outgrowth, synaptogenesis, cAMP signaling, potassium channels, NMDA receptor, NF-κB, cell adhesion, excitotoxicity, neurodegeneration
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Humans, Membrane Proteins, Mutation, Nervous System, Neurons, Protein Processing, Post-Translational, Synapses, Amyloid beta-Peptides, Neurites, Amyloid beta-Protein Precursor, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review